SEC Tracker
Get the app

SI-BONE SIBN

SI-BONE Q3 FY25: revenue $48.7M, up 21%; diluted EPS −$0.11

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers SI-BONE reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$48.7M+21% from $40.3M in Q3 FY2410-Q income statement, on EDGAR
  2. Net income−$4.6MAgainst −$6.6M in Q3 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$0.11Against −$0.16 in Q3 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$26.5M−12% from $30.2M in Q3 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations$2.3M+673% from $302K in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when SI-BONE files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Biolife Solutions BLFS public float $845M, Jun 30, 2025
  2. Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old
  3. Mimedx Group MDXG public float $719M, Jun 30, 2025
  4. Heartflow HTFL
  5. Integra Lifesciences Holdings IART public float $925M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.